Lexicon sinks as FDA advisers vote against add-on drug for type 1 diabetes

Lexicon Pharmaceuticals

01/11/2024 12:25

** Shares of drug developer Lexicon Pharmaceuticals  LXRX.O 
fall ~35.9% to $1.25 premarket
    ** Late on Thursday, advisers to the U.S. FDA voted against
recommending Lexicon's add-on treatment to insulin therapy for
managing blood glucose levels in adults with type 1 diabetes and
chronic kidney disease
    ** The panel voted 11-3 against the drug sotagliflozin
    ** The panel members said they were "disappointed" over the
lack of clinical data as the subgroup of patients who might
benefit the most were not prospectively studied
    ** Up to last close, stock up 27.5% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))